A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

What Was Tested

In this phase 4 trial, researchers set out to test Tirzepatide.

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition.

Eligible participants must be registered patients at a participating site.

Participation in the study will last about 260 weeks.

It had two arms (groups): Tirzepatide + Standard of Care (experimental) and Standard of Care (active comparator).

Participants will receive tirzepatide subcutaneously (SC) + standard of care.

The registry classes the interventions as drug and other.

Who Took Part

Enrollment: 3000 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2). Have at least one weight related comorbid condition. Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity).

The full record lists 4 inclusion and 2 exclusion criteria; among the exclusions: have type 1 diabetes, type 2 diabetes, or any other types of diabetes; have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-11-24 with completion listed for 2029-07.

It ran at 30 sites in United Kingdom (30).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percent Change from Baseline in Body Weight (time frame: Baseline, 24 months).

It also tracked 16 secondary outcomes, for example Time from Baseline to Onset of Type 2 Diabetes, Percentage of Participants Converting from Prediabetes to Normoglycemia, Percentage of Participants with Normoglycemia at Baseline who Develop Prediabetes, Change from Baseline in Hemoglobin A1c (HbA1c), Percentage of Participants who Develop a New Obesity-Related Complication and Change from Baseline in Waist Circumference.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Tirzepatide in 3000 people.

With 3000 participants it is a large trial for this field.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.